BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.35
-1.08 (-12.81%)
At close: Nov 4, 2024, 4:00 PM
7.27
-0.08 (-1.07%)
Pre-market: Nov 5, 2024, 9:17 AM EST
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 536 employees as of December 31, 2023. The number of employees increased by 5 or 0.94% compared to the previous year.
Employees
536
Change (1Y)
5
Growth (1Y)
0.94%
Revenue / Employee
$769,737
Profits / Employee
-$231,002
Market Cap
1.52B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
NeoGenomics | 2,100 |
NovoCure | 1,453 |
Certara | 1,391 |
Galapagos NV | 1,123 |
Recursion Pharmaceuticals | 500 |
Nurix Therapeutics | 284 |
Celldex Therapeutics | 160 |
Neumora Therapeutics | 124 |
BCRX News
- 22 hours ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - BioCryst to Report Third Quarter 2024 Financial Results on November 4 - GlobeNewsWire
- 22 days ago - BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) - GlobeNewsWire
- 4 weeks ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome - GlobeNewsWire
- 5 weeks ago - U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile - GlobeNewsWire
- 7 weeks ago - BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks - GlobeNewsWire
- 2 months ago - BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium - GlobeNewsWire